{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T08:00:35Z","timestamp":1789891235359,"version":"4.0.1"},"reference-count":96,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T00:00:00Z","timestamp":1789862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T00:00:00Z","timestamp":1789862400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Lab Anim Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Neurofibromatosis is a genetic disorder characterized by nervous system tumors arising primarily from\n                    <jats:italic>NF1<\/jats:italic>\n                    or\n                    <jats:italic>NF2<\/jats:italic>\n                    mutations. Given the complexity of the genetic background and heterogeneity of associated tumor phenotypes in neurofibromatosis, mechanistic investigations rely heavily on experimental animal models. Human tissue-based studies alone cannot fully elucidate causal relationships, temporal dynamics, modifier gene effects, or cell type-specific contributions to tumor development, progression, and microenvironmental regulation. Consequently, various animal models have been developed, including genetically engineered mouse models, large-animal systems, alternative vertebrate models, and transplantation-based approaches. These experimental platforms enable the controlled manipulation of gene dosage, lineage-specific gene deletion, immune modulation, targeted disruption of stromal and extracellular matrix components, and evaluation of therapeutic response and drug resistance mechanisms. Animal models have helped demonstrate the cell-autonomous and non-cell-autonomous mechanisms underlying neurofibromatosis tumorigenesis. Furthermore, sustained tumor maintenance and progression require coordinated interactions between neoplastic cells and their surrounding microenvironment. Notably, these experimental systems offer a temporal resolution not achievable in clinical specimens, demonstrating that microenvironmental alterations may precede overt tumor formation. Such findings depict the tumor microenvironment (TME) as an active contributor to disease rather than merely as a consequence of tumor growth. In this review, we evaluate the experimental scope, methodological strengths, and inherent limitations of current animal models used in neurofibromatosis research, with emphasis on their utility in elucidating interactions within the TME and non-neoplastic disease manifestations. This work characterizes model-specific advantages and constraints to emphasize the continued importance of animal models as essential tools for hypothesis-driven investigation and translational development in elucidating the various attributes of neurofibromatosis.\n                  <\/jats:p>","DOI":"10.1186\/s42826-026-00298-2","type":"journal-article","created":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T06:05:56Z","timestamp":1789884356000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Advancing neurofibromatosis research: a comparative review of animal models and their utility in dissecting the tumor microenvironment"],"prefix":"10.1186","volume":"42","author":[{"given":"Ai-Lun","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7380-8479","authenticated-orcid":false,"given":"Ya-Mei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,20]]},"reference":[{"issue":"3","key":"298_CR1","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/2047-783X-14-3-102","volume":"14","author":"PA Gerber","year":"2009","unstructured":"Gerber PA, Antal AS, Neumann NJ, Homey B, Matuschek C, Peiper M, et al. Neurofibromatosis Eur J Med Res. 2009;14(3):102\u20135.","journal-title":"Neurofibromatosis Eur J Med Res"},{"key":"298_CR2","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/B978-0-444-52891-9.00039-7","volume":"111","author":"BR Korf","year":"2013","unstructured":"Korf BR, Neurofibromatosis. Handb Clin Neurol. 2013;111:333\u201340.","journal-title":"Handb Clin Neurol"},{"issue":"1","key":"298_CR3","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1186\/s40478-025-02075-z","volume":"13","author":"P Pulh","year":"2025","unstructured":"Pulh P, Coulpier F, Onfroy A, Oubrou L, Zhang W, Toledano L, et al. Unraveling the development of cutaneous neurofibromas in neurofibromatosis type 1. Acta Neuropathol Commun. 2025;13(1):158.","journal-title":"Acta Neuropathol Commun"},{"key":"298_CR4","doi-asserted-by":"publisher","first-page":"101818","DOI":"10.1016\/j.eclinm.2022.101818","volume":"56","author":"C Carton","year":"2023","unstructured":"Carton C, Evans DG, Blanco I, Friedrich RE, Ferner RE, Farschtschi S, et al. ERN GENTURIS tumour surveillance guidelines for individuals with neurofibromatosis type 1. EClinicalMedicine. 2023;56:101818.","journal-title":"EClinicalMedicine"},{"key":"298_CR5","doi-asserted-by":"publisher","first-page":"17004","DOI":"10.1038\/nrdp.2017.4","volume":"3","author":"DH Gutmann","year":"2017","unstructured":"Gutmann DH, Ferner RE, Listernick RH, Korf BR, Wolters PL, Johnson KJ. Neurofibromatosis type 1. Nat Rev Dis Primers. 2017;3:17004.","journal-title":"Nat Rev Dis Primers"},{"key":"298_CR6","unstructured":"Friedman JM et al. Neurofibromatosis 1. In: Adam MP, Bick S, Mirzaa GM, editors. GeneReviews\u00ae [Internet]. Seattle (WA): University of Washington, Seattle; 1993\u20132026."},{"issue":"8","key":"298_CR7","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1038\/s41436-021-01170-5","volume":"23","author":"E Legius","year":"2021","unstructured":"Legius E, Messiaen L, Wolkenstein P, Pancza P, Avery RA, Berman Y, et al. Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: an international consensus recommendation. Genet Med. 2021;23(8):1506\u201313.","journal-title":"Genet Med"},{"issue":"5","key":"298_CR8","doi-asserted-by":"publisher","first-page":"e240271","DOI":"10.1148\/rg.240271","volume":"45","author":"S Ansari","year":"2025","unstructured":"Ansari S, Dixe de Oliveira Santo I, Yazdian Anari P, Badawy M, Flug JA. Plexiform Neurofibroma Radiographics. 2025;45(5):e240271.","journal-title":"Plexiform Neurofibroma Radiographics"},{"issue":"9679","key":"298_CR9","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.1016\/S0140-6736(09)60259-2","volume":"373","author":"AR Asthagiri","year":"2009","unstructured":"Asthagiri AR, Parry DM, Butman JA, Kim HJ, Tsilou ET, Zhuang Z, et al. Neurofibromatosis type 2. Lancet. 2009;373(9679):1974\u201386.","journal-title":"Lancet"},{"key":"298_CR10","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/B978-0-444-62702-5.00005-6","volume":"132","author":"DG Evans","year":"2015","unstructured":"Evans DG. Neurofibromatosis type 2. Handb Clin Neurol. 2015;132:87\u201396.","journal-title":"Handb Clin Neurol"},{"key":"298_CR11","first-page":"91","volume":"70","author":"GR Evans","year":"2011","unstructured":"Evans GR, Lloyd SKW, Ramsden RT. Neurofibromatosis type 2. Adv Otorhinolaryngol. 2011;70:91\u20138.","journal-title":"Adv Otorhinolaryngol"},{"issue":"4","key":"298_CR12","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1007\/s00401-019-02029-5","volume":"139","author":"S Coy","year":"2020","unstructured":"Coy S, Rashid R, Stemmer-Rachamimov A, Santagata S. An update on the CNS manifestations of neurofibromatosis type 2. Acta Neuropathol. 2020;139(4):643\u201365.","journal-title":"Acta Neuropathol"},{"issue":"4","key":"298_CR13","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.spen.2015.10.008","volume":"22","author":"M Ruggieri","year":"2015","unstructured":"Ruggieri M, Pratic\u00f2 AD, Evans DG. Diagnosis, Management, and New Therapeutic Options in Childhood Neurofibromatosis Type 2 and Related Forms. Semin Pediatr Neurol. 2015;22(4):240\u201358.","journal-title":"Semin Pediatr Neurol"},{"issue":"1","key":"298_CR14","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s12935-023-02940-8","volume":"23","author":"MA Ghalavand","year":"2023","unstructured":"Ghalavand MA, Asghari A, Farhadi M, Taghizadeh-Hesary F, Garshasbi M, Falah M. The genetic landscape and possible therapeutics of neurofibromatosis type 2. Cancer Cell Int. 2023;23(1):99.","journal-title":"Cancer Cell Int"},{"issue":"4","key":"298_CR15","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1148\/rg.210235","volume":"42","author":"MX Wang","year":"2022","unstructured":"Wang MX, Dillman JR, Guccione J, Habiba A, Maher M, Kamel S, et al. Neurofibromatosis from Head to Toe: What the Radiologist Needs to Know. Radiographics. 2022;42(4):1123\u201344.","journal-title":"Radiographics"},{"issue":"3","key":"298_CR16","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1007\/s00401-011-0928-6","volume":"123","author":"SL Carroll","year":"2012","unstructured":"Carroll SL. Molecular mechanisms promoting the pathogenesis of Schwann cell neoplasms. Acta Neuropathol. 2012;123(3):321\u201348.","journal-title":"Acta Neuropathol"},{"issue":"1","key":"298_CR17","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.brainresbull.2011.08.005","volume":"88","author":"NM Brossier","year":"2012","unstructured":"Brossier NM, Carroll SL. Genetically engineered mouse models shed new light on the pathogenesis of neurofibromatosis type I-related neoplasms of the peripheral nervous system. Brain Res Bull. 2012;88(1):58\u201371.","journal-title":"Brain Res Bull"},{"issue":"27","key":"298_CR18","doi-asserted-by":"publisher","first-page":"e2506823122","DOI":"10.1073\/pnas.2506823122","volume":"122","author":"HN Vasudevan","year":"2025","unstructured":"Vasudevan HN, Arang N, Sacconi Nunez M, Kennedy P, Payne E, Mohabeer S, et al. A transcriptomic, proteomic, and functional genetic atlas dissects neurofibromin function in the peripheral nervous system. Proc Natl Acad Sci U S A. 2025;122(27):e2506823122.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"298_CR19","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.5604\/17322693.1185213","volume":"69","author":"A Abramowicz","year":"2015","unstructured":"Abramowicz A, Gos M. [Neurofibromin - protein structure and cellular functions in the context of neurofibromatosis type I pathogenesis]. Postepy Hig Med Dosw (Online). 2015;69:1331\u201348.","journal-title":"Postepy Hig Med Dosw (Online)"},{"issue":"13","key":"298_CR20","doi-asserted-by":"publisher","first-page":"4686","DOI":"10.1158\/0008-5472.CAN-10-4577","volume":"71","author":"LQ Le","year":"2011","unstructured":"Le LQ, Liu C, Shipman T, Chen Z, Suter U, Parada LF. Susceptible stages in Schwann cells for NF1-associated plexiform neurofibroma development. Cancer Res. 2011;71(13):4686\u201395.","journal-title":"Cancer Res"},{"issue":"2","key":"298_CR21","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/S0002-9440(10)63992-2","volume":"158","author":"D Muir","year":"2001","unstructured":"Muir D, Neubauer D, Lim IT, Yachnis AT, Wallace MR. Tumorigenic properties of neurofibromin-deficient neurofibroma Schwann cells. Am J Pathol. 2001;158(2):501\u201313.","journal-title":"Am J Pathol"},{"issue":"12","key":"298_CR22","doi-asserted-by":"publisher","first-page":"2997","DOI":"10.1158\/1078-0432.CCR-19-2706","volume":"26","author":"JL Kohlmeyer","year":"2020","unstructured":"Kohlmeyer JL, Kaemmer CA, Pulliam C, Maharjan CK, Samayoa AM, Major HJ, et al. RABL6A Is an Essential Driver of MPNSTs that Negatively Regulates the RB1 Pathway and Sensitizes Tumor Cells to CDK4\/6 Inhibitors. Clin Cancer Res. 2020;26(12):2997\u20133011.","journal-title":"Clin Cancer Res"},{"issue":"24","key":"298_CR23","doi-asserted-by":"publisher","first-page":"3955","DOI":"10.3390\/cancers17243955","volume":"17","author":"S Busciglio","year":"2025","unstructured":"Busciglio S, Cannizzaro IR, Luberto A, Taiani A, Moschella B, Ambrosini E, et al. The Pathogenesis of the Neurofibroma-to-Sarcoma Transition in Neurofibromatosis Type I: From Molecular Profiles to Diagnostic Applications. Cancers (Basel). 2025;17(24):3955.","journal-title":"Cancers (Basel)"},{"issue":"3","key":"298_CR24","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1158\/2159-8290.CD-22-0786","volume":"13","author":"I Cortes-Ciriano","year":"2023","unstructured":"Cortes-Ciriano I, Steele CD, Piculell K, Al-Ibraheemi A, Eulo V, Bui MM, et al. Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA. Cancer Discov. 2023;13(3):654\u201371.","journal-title":"Cancer Discov"},{"issue":"47","key":"298_CR25","doi-asserted-by":"publisher","first-page":"39524","DOI":"10.1074\/jbc.M503707200","volume":"280","author":"T Ozawa","year":"2005","unstructured":"Ozawa T, Araki N, Yunoue S, Tokuo H, Feng L, Patrakitkomjorn S, et al. The neurofibromatosis type 1 gene product neurofibromin enhances cell motility by regulating actin filament dynamics via the Rho-ROCK-LIMK2-cofilin pathway. J Biol Chem. 2005;280(47):39524\u201333.","journal-title":"J Biol Chem"},{"key":"298_CR26","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.semcdb.2016.02.007","volume":"52","author":"E Rad","year":"2016","unstructured":"Rad E, Tee AR. Neurofibromatosis type 1: Fundamental insights into cell signalling and cancer. Semin Cell Dev Biol. 2016;52:39\u201346.","journal-title":"Semin Cell Dev Biol"},{"issue":"2","key":"298_CR27","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1002\/jcp.10349","volume":"197","author":"T Corral","year":"2003","unstructured":"Corral T, Jim\u00e9nez M, Hern\u00e1ndez-Mu\u00f1oz I, P\u00e9rez de Castro I, Pellicer A. NF1 modulates the effects of Ras oncogenes: evidence of other NF1 function besides its GAP activity. J Cell Physiol. 2003;197(2):214\u201324.","journal-title":"J Cell Physiol"},{"issue":"1","key":"298_CR28","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s12964-021-00773-4","volume":"19","author":"SM Weber","year":"2021","unstructured":"Weber SM, Brossier NM, Prechtl A, Barnes S, Wilson LS, Brosius SN, et al. R-Ras subfamily proteins elicit distinct physiologic effects and phosphoproteome alterations in neurofibromin-null MPNST cells. Cell Commun Signal. 2021;19(1):95.","journal-title":"Cell Commun Signal"},{"issue":"8","key":"298_CR29","doi-asserted-by":"publisher","first-page":"e136","DOI":"10.1111\/j.1600-0625.2009.01017.x","volume":"19","author":"Y Arima","year":"2010","unstructured":"Arima Y, Hayashi H, Kamata K, Goto TM, Sasaki M, Kuramochi A, et al. Decreased expression of neurofibromin contributes to epithelial-mesenchymal transition in neurofibromatosis type 1. Exp Dermatol. 2010;19(8):e136\u201341.","journal-title":"Exp Dermatol"},{"issue":"3","key":"298_CR30","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1002\/glia.24308","volume":"71","author":"SW Doutt","year":"2023","unstructured":"Doutt SW, Longo JF, Carroll SL. LPAR1 and aberrantly expressed LPAR3 differentially promote the migration and proliferation of malignant peripheral nerve sheath tumor cells. Glia. 2023;71(3):742\u201357.","journal-title":"Glia"},{"issue":"4","key":"298_CR31","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1002\/jcb.22301","volume":"108","author":"A Nasir-ud-Din, Kaleem","year":"2009","unstructured":"Nasir-ud-Din, Kaleem A, Ahmad I, Walker-Nasir E, Hoessli DC, Shakoori AR. Effect on the Ras\/Raf signaling pathway of post-translational modifications of neurofibromin: in silico study of protein modification responsible for regulatory pathways. J Cell Biochem. 2009;108(4):816\u201324.","journal-title":"J Cell Biochem"},{"issue":"11","key":"298_CR32","doi-asserted-by":"publisher","first-page":"2365","DOI":"10.3390\/cells9112365","volume":"9","author":"M Bergoug","year":"2020","unstructured":"Bergoug M, Doudeau M, Godin F, Mosrin C, Vall\u00e9e B, B\u00e9n\u00e9detti H. Neurofibromin Structure, Functions and Regulation. Cells. 2020;9(11):2365.","journal-title":"Cells"},{"issue":"5447","key":"298_CR33","doi-asserted-by":"publisher","first-page":"2172","DOI":"10.1126\/science.286.5447.2172","volume":"286","author":"K Cichowski","year":"1999","unstructured":"Cichowski K, Shih TS, Schmitt E, Santiago S, Reilly K, McLaughlin ME, et al. Mouse models of tumor development in neurofibromatosis type 1. Science. 1999;286(5447):2172\u20136.","journal-title":"Science"},{"issue":"4","key":"298_CR34","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1007\/s00401-013-1209-3","volume":"127","author":"SN Brosius","year":"2014","unstructured":"Brosius SN, Turk AN, Byer SJ, Brossier NM, Kohli L, Whitmire A, et al. Neuregulin-1 overexpression and Trp53 haploinsufficiency cooperatively promote de novo malignant peripheral nerve sheath tumor pathogenesis. Acta Neuropathol. 2014;127(4):573\u201391.","journal-title":"Acta Neuropathol"},{"issue":"6871","key":"298_CR35","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1038\/nature711","volume":"415","author":"RM Costa","year":"2002","unstructured":"Costa RM, Federov NB, Kogan JH, Murphy GG, Stern J, Ohno M, et al. Mechanism for the learning deficits in a mouse model of neurofibromatosis type 1. Nature. 2002;415(6871):526\u201330.","journal-title":"Nature"},{"issue":"22","key":"298_CR36","doi-asserted-by":"publisher","first-page":"4515","DOI":"10.1093\/hmg\/ddq382","volume":"19","author":"JA Brown","year":"2010","unstructured":"Brown JA, Emnett RJ, White CR, Yuede CM, Conyers SB, O\u2019Malley KL, et al. Reduced striatal dopamine underlies the attention system dysfunction in neurofibromatosis-1 mutant mice. Hum Mol Genet. 2010;19(22):4515\u201328.","journal-title":"Hum Mol Genet"},{"issue":"5","key":"298_CR37","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1016\/j.celrep.2014.07.054","volume":"8","author":"MA Wolman","year":"2014","unstructured":"Wolman MA, de Groh ED, McBride SM, Jongens TA, Granato M, Epstein JA. Modulation of cAMP and ras signaling pathways improves distinct behavioral deficits in a zebrafish model of neurofibromatosis type 1. Cell Rep. 2014;8(5):1265\u201370.","journal-title":"Cell Rep"},{"issue":"10","key":"298_CR38","doi-asserted-by":"publisher","first-page":"e3000477","DOI":"10.1371\/journal.pbio.3000477","volume":"17","author":"LP Sutton","year":"2019","unstructured":"Sutton LP, Muntean BS, Ostrovskaya O, Zucca S, Dao M, Orlandi C, et al. NF1-cAMP signaling dissociates cell type-specific contributions of striatal medium spiny neurons to reward valuation and motor control. PLoS Biol. 2019;17(10):e3000477.","journal-title":"PLoS Biol"},{"issue":"4","key":"298_CR39","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/S1474-4422(07)70075-3","volume":"6","author":"RE Ferner","year":"2007","unstructured":"Ferner RE. Neurofibromatosis 1 and neurofibromatosis 2: a twenty first century perspective. Lancet Neurol. 2007;6(4):340\u201351.","journal-title":"Lancet Neurol"},{"issue":"11","key":"298_CR40","doi-asserted-by":"publisher","first-page":"5850","DOI":"10.3390\/ijms22115850","volume":"22","author":"R Tamura","year":"2021","unstructured":"Tamura R. Current Understanding of Neurofibromatosis Type 1, 2, and Schwannomatosis. Int J Mol Sci. 2021;22(11):5850.","journal-title":"Int J Mol Sci"},{"issue":"9","key":"298_CR41","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/S0166-2236(96)10044-8","volume":"19","author":"M Lutchman","year":"1996","unstructured":"Lutchman M, Rouleau GA. Neurofibromatosis type 2: a new mechanism of tumor suppression. Trends Neurosci. 1996;19(9):373\u20137.","journal-title":"Trends Neurosci"},{"issue":"2","key":"298_CR42","doi-asserted-by":"publisher","first-page":"690","DOI":"10.3390\/ijms22020690","volume":"22","author":"S Bachir","year":"2021","unstructured":"Bachir S, Shah S, Shapiro S, Koehler A, Mahammedi A, Samy RN, et al. Neurofibromatosis Type 2 (NF2) and the Implications for Vestibular Schwannoma and Meningioma Pathogenesis. Int J Mol Sci. 2021;22(2):690.","journal-title":"Int J Mol Sci"},{"issue":"2","key":"298_CR43","first-page":"M73","volume":"1471","author":"AI McClatchey","year":"2001","unstructured":"McClatchey AI, Cichowski K. Mouse models of neurofibromatosis. Biochim Biophys Acta. 2001;1471(2):M73\u201380.","journal-title":"Biochim Biophys Acta"},{"issue":"4","key":"298_CR44","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1038\/sj.neo.7900249","volume":"4","author":"DH Gutmann","year":"2002","unstructured":"Gutmann DH, Giovannini M. Mouse models of neurofibromatosis 1 and 2. Neoplasia. 2002;4(4):279\u201390.","journal-title":"Neoplasia"},{"issue":"8","key":"298_CR45","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1016\/S1474-4422(14)70063-8","volume":"13","author":"AC Hirbe","year":"2014","unstructured":"Hirbe AC, Gutmann DH. Neurofibromatosis type 1: a multidisciplinary approach to care. Lancet Neurol. 2014;13(8):834\u201343.","journal-title":"Lancet Neurol"},{"issue":"8","key":"298_CR46","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1016\/j.jid.2023.01.042","volume":"143","author":"V Staedtke","year":"2023","unstructured":"Staedtke V, Topilko P, Le LQ, Grimes K, Largaespada DA, Cagan RL, et al. Existing and Developing Preclinical Models for Neurofibromatosis Type 1-Related Cutaneous Neurofibromas. J Invest Dermatol. 2023;143(8):1378\u201387.","journal-title":"J Invest Dermatol"},{"issue":"21","key":"298_CR47","doi-asserted-by":"publisher","first-page":"4720","DOI":"10.1158\/0008-5472.CAN-19-1429","volume":"80","author":"KE Chaney","year":"2020","unstructured":"Chaney KE, Perrino MR, Kershner LJ, Patel AV, Wu J, Choi K, et al. Cdkn2a Loss in a Model of Neurofibroma Demonstrates Stepwise Tumor Progression to Atypical Neurofibroma and MPNST. Cancer Res. 2020;80(21):4720\u201330.","journal-title":"Cancer Res"},{"issue":"1","key":"298_CR48","doi-asserted-by":"publisher","first-page":"e139807","DOI":"10.1172\/JCI139807","volume":"131","author":"J Mo","year":"2021","unstructured":"Mo J, Anastasaki C, Chen Z, Shipman T, Papke J, Yin K, et al. Humanized neurofibroma model from induced pluripotent stem cells delineates tumor pathogenesis and developmental origins. J Clin Invest. 2021;131(1):e139807.","journal-title":"J Clin Invest"},{"issue":"1","key":"298_CR49","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1158\/2159-8290.CD-18-0156","volume":"9","author":"KJ Radomska","year":"2019","unstructured":"Radomska KJ, Coulpier F, Gresset A, Schmitt A, Debbiche A, Lemoine S, et al. Cellular Origin, Tumor Progression, and Pathogenic Mechanisms of Cutaneous Neurofibromas Revealed by Mice with Nf1 Knockout in Boundary Cap Cells. Cancer Discov. 2019;9(1):130\u201347.","journal-title":"Cancer Discov"},{"issue":"1","key":"298_CR50","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1002\/humu.24290","volume":"43","author":"A Long","year":"2022","unstructured":"Long A, Liu H, Liu J, Daniel M, Bedwell DM, Korf B, et al. Analysis of patient-specific NF1 variants leads to functional insights for Ras signaling that can impact personalized medicine. Hum Mutat. 2022;43(1):30\u201341.","journal-title":"Hum Mutat"},{"issue":"6","key":"298_CR51","doi-asserted-by":"publisher","first-page":"e0301040","DOI":"10.1371\/journal.pone.0301040","volume":"19","author":"C Plante","year":"2024","unstructured":"Plante C, Mohamad T, Hewa Bostanthirige D, Renaud M, Sidhu H, ElChoueiry M, et al. Revisiting the NPcis mouse model: A new tool to model plexiform neurofibroma. PLoS ONE. 2024;19(6):e0301040.","journal-title":"PLoS ONE"},{"issue":"1","key":"298_CR52","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1002\/ana.20337","volume":"57","author":"ML Bajenaru","year":"2005","unstructured":"Bajenaru ML, Garbow JR, Perry A, Hernandez MR, Gutmann DH. Natural history of neurofibromatosis 1-associated optic nerve glioma in mice. Ann Neurol. 2005;57(1):119\u201327.","journal-title":"Ann Neurol"},{"issue":"24","key":"298_CR53","doi-asserted-by":"publisher","first-page":"5577","DOI":"10.1242\/dev.02162","volume":"132","author":"Y Zhu","year":"2005","unstructured":"Zhu Y, Harada T, Liu L, Lush ME, Guignard F, Harada C, et al. Inactivation of NF1 in CNS causes increased glial progenitor proliferation and optic glioma formation. Development. 2005;132(24):5577\u201388.","journal-title":"Development"},{"issue":"6","key":"298_CR54","first-page":"808","volume":"19","author":"JA Toonen","year":"2017","unstructured":"Toonen JA, Ma Y, Gutmann DH. Defining the temporal course of murine neurofibromatosis-1 optic gliomagenesis reveals a therapeutic window to attenuate retinal dysfunction. Neuro Oncol. 2017;19(6):808\u201319.","journal-title":"Neuro Oncol"},{"issue":"8","key":"298_CR55","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1038\/nm.3583","volume":"20","author":"J de la Croix Ndong","year":"2014","unstructured":"de la Croix Ndong J, Makowski AJ, Uppuganti S, Vignaux G, Ono K, Perrien DS, et al. Asfotase-\u03b1 improves bone growth, mineralization and strength in mouse models of neurofibromatosis type-1. Nat Med. 2014;20(8):904\u201310.","journal-title":"Nat Med"},{"issue":"11","key":"298_CR56","doi-asserted-by":"publisher","first-page":"2880","DOI":"10.1172\/JCI29092","volume":"116","author":"FC Yang","year":"2006","unstructured":"Yang FC, Chen S, Robling AG, Yu X, Nebesio TD, Yan J, et al. Hyperactivation of p21ras and PI3K cooperate to alter murine and human neurofibromatosis type 1-haploinsufficient osteoclast functions. J Clin Invest. 2006;116(11):2880\u201391.","journal-title":"J Clin Invest"},{"issue":"29","key":"298_CR57","doi-asserted-by":"publisher","first-page":"13141","DOI":"10.1073\/pnas.1004829107","volume":"107","author":"C Shilyansky","year":"2010","unstructured":"Shilyansky C, Karlsgodt KH, Cummings DM, Sidiropoulou K, Hardt M, James AS, et al. Neurofibromin regulates corticostriatal inhibitory networks during working memory performance. Proc Natl Acad Sci U S A. 2010;107(29):13141\u20136.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"298_CR58","doi-asserted-by":"crossref","unstructured":"Ye M, Bore A, Richon S, Dangles-Marie V, Pasmant E, Margueron R et al. An orthotopic sciatic nerve xenograft for neurofibromatosis type 1 neurofibromas. J Vis Exp. 2025;(224).","DOI":"10.3791\/68694"},{"issue":"6","key":"298_CR59","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1002\/jnr.21226","volume":"85","author":"GQ Perrin","year":"2007","unstructured":"Perrin GQ, Fishbein L, Thomson SA, Thomas SL, Stephens K, Garbern JY, et al. Plexiform-like neurofibromas develop in the mouse by intraneural xenograft of an NF1 tumor-derived Schwann cell line. J Neurosci Res. 2007;85(6):1347\u201357.","journal-title":"J Neurosci Res"},{"issue":"1","key":"298_CR60","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.nhtm.2014.08.001","volume":"2","author":"T Denayer","year":"2014","unstructured":"Denayer T, St\u00f6hr T, Van Roy M. Animal models in translational medicine: Validation and prediction. Eur J Mol Clin Med. 2014;2(1):5.","journal-title":"Eur J Mol Clin Med"},{"issue":"4","key":"298_CR61","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.3390\/ijms22041954","volume":"22","author":"SH Osum","year":"2021","unstructured":"Osum SH, Watson AL, Largaespada DA. Spontaneous and Engineered Large Animal Models of Neurofibromatosis Type 1. Int J Mol Sci. 2021;22(4):1954.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"298_CR62","doi-asserted-by":"publisher","first-page":"5046","DOI":"10.1038\/s41598-020-61251-4","volume":"10","author":"J Uthoff","year":"2020","unstructured":"Uthoff J, Larson J, Sato TS, Hammond E, Schroeder KE, Rohret F, et al. Longitudinal phenotype development in a minipig model of neurofibromatosis type 1. Sci Rep. 2020;10(1):5046.","journal-title":"Sci Rep"},{"issue":"12","key":"298_CR63","doi-asserted-by":"publisher","first-page":"e120402","DOI":"10.1172\/jci.insight.120402","volume":"3","author":"KA White","year":"2018","unstructured":"White KA, Swier VJ, Cain JT, Kohlmeyer JL, Meyerholz DK, Tanas MR, et al. A porcine model of neurofibromatosis type 1 that mimics the human disease. JCI Insight. 2018;3(12):e120402.","journal-title":"JCI Insight"},{"key":"298_CR64","doi-asserted-by":"publisher","first-page":"1253659","DOI":"10.3389\/fonc.2023.1253659","volume":"13","author":"DT McLean","year":"2023","unstructured":"McLean DT, Meudt JJ, Lopez Rivera LD, Schomberg DT, Pavelec DM, Duellman TT, et al. Single-cell RNA sequencing of neurofibromas reveals a tumor microenvironment favorable for neural regeneration and immune suppression in a neurofibromatosis type 1 porcine model. Front Oncol. 2023;13:1253659.","journal-title":"Front Oncol"},{"issue":"6","key":"298_CR65","first-page":"881","volume":"5","author":"J Shin","year":"2012","unstructured":"Shin J, Padmanabhan A, de Groh ED, Lee JS, Haidar S, Dahlberg S, et al. Zebrafish neurofibromatosis type 1 genes have redundant functions in tumorigenesis and embryonic development. Dis Model Mech. 2012;5(6):881\u201394.","journal-title":"Dis Model Mech"},{"issue":"13","key":"298_CR66","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1101\/gad.14.13.1617","volume":"14","author":"M Giovannini","year":"2000","unstructured":"Giovannini M, Robanus-Maandag E, van der Valk M, Niwa-Kawakita M, Abramowski V, Goutebroze L, et al. Conditional biallelic Nf2 mutation in the mouse promotes manifestations of human neurofibromatosis type 2. Genes Dev. 2000;14(13):1617\u201330.","journal-title":"Genes Dev"},{"issue":"1","key":"298_CR67","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/hmg\/ddu414","volume":"24","author":"JR Gehlhausen","year":"2015","unstructured":"Gehlhausen JR, Park SJ, Hickox AE, Shew M, Staser K, Rhodes SD, et al. A murine model of neurofibromatosis type 2 that accurately phenocopies human schwannoma formation. Hum Mol Genet. 2015;24(1):1\u20138.","journal-title":"Hum Mol Genet"},{"issue":"17","key":"298_CR68","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1093\/hmg\/ddab106","volume":"30","author":"E Hawley","year":"2021","unstructured":"Hawley E, Gehlhausen J, Karchugina S, Chow HY, Araiza-Olivera D, Radu M, et al. PAK1 inhibition reduces tumor size and extends the lifespan of mice in a genetically engineered mouse model of Neurofibromatosis Type 2 (NF2). Hum Mol Genet. 2021;30(17):1607\u201317.","journal-title":"Hum Mol Genet"},{"issue":"2","key":"298_CR69","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1038\/s41596-018-0105-7","volume":"14","author":"J Chen","year":"2019","unstructured":"Chen J, Landegger LD, Sun Y, Ren J, Maimon N, Wu L, et al. A cerebellopontine angle mouse model for the investigation of tumor biology, hearing, and neurological function in NF2-related vestibular schwannoma. Nat Protoc. 2019;14(2):541\u201355.","journal-title":"Nat Protoc"},{"issue":"11","key":"298_CR70","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.3390\/cancers16111961","volume":"16","author":"S Lu","year":"2024","unstructured":"Lu S, Yin Z, Chen J, Wu L, Sun Y, Gao X, et al. Integrating Ataxia Evaluation into Tumor-Induced Hearing Loss Model to Comprehensively Study NF2-Related Schwannomatosis. Cancers (Basel). 2024;16(11):1961.","journal-title":"Cancers (Basel)"},{"issue":"39","key":"298_CR71","doi-asserted-by":"publisher","first-page":"5781","DOI":"10.1038\/s41388-021-01979-z","volume":"40","author":"C Jiang","year":"2021","unstructured":"Jiang C, McKay RM, Le LQ. Tumorigenesis in neurofibromatosis type 1: role of the microenvironment. Oncogene. 2021;40(39):5781\u20137.","journal-title":"Oncogene"},{"issue":"1","key":"298_CR72","doi-asserted-by":"publisher","first-page":"2785","DOI":"10.1038\/s41467-022-30466-6","volume":"13","author":"C Anastasaki","year":"2022","unstructured":"Anastasaki C, Mo J, Chen JK, Chatterjee J, Pan Y, Scheaffer SM, et al. Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1. Nat Commun. 2022;13(1):2785.","journal-title":"Nat Commun"},{"issue":"12","key":"298_CR73","doi-asserted-by":"publisher","first-page":"e168227","DOI":"10.1172\/JCI168227","volume":"133","author":"C Jiang","year":"2023","unstructured":"Jiang C, Kumar A, Yu Z, Shipman T, Wang Y, McKay RM, et al. Basement membrane proteins in extracellular matrix characterize NF1 neurofibroma development and response to MEK inhibitor. J Clin Invest. 2023;133(12):e168227.","journal-title":"J Clin Invest"},{"issue":"3","key":"298_CR74","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/j.cell.2008.08.041","volume":"135","author":"FC Yang","year":"2008","unstructured":"Yang FC, Ingram DA, Chen S, Zhu Y, Yuan J, Li X, et al. Nf1-dependent tumors require a microenvironment containing Nf1+\/\u2013- and c-kit-dependent bone marrow. Cell. 2008;135(3):437\u201348.","journal-title":"Cell"},{"issue":"7","key":"298_CR75","doi-asserted-by":"publisher","first-page":"2848","DOI":"10.1172\/JCI99424","volume":"128","author":"CP Liao","year":"2018","unstructured":"Liao CP, Booker RC, Brosseau JP, Chen Z, Mo J, Tchegnon E, et al. Contributions of inflammation and tumor microenvironment to neurofibroma tumorigenesis. J Clin Invest. 2018;128(7):2848\u201361.","journal-title":"J Clin Invest"},{"issue":"6","key":"298_CR76","doi-asserted-by":"publisher","first-page":"3125","DOI":"10.2353\/ajpath.2010.100369","volume":"177","author":"S Chen","year":"2010","unstructured":"Chen S, Burgin S, McDaniel A, Li X, Yuan J, Chen M, et al. Nf1-\/- Schwann cell-conditioned medium modulates mast cell degranulation by c-Kit-mediated hyperactivation of phosphatidylinositol 3-kinase. Am J Pathol. 2010;177(6):3125\u201332.","journal-title":"Am J Pathol"},{"issue":"1","key":"298_CR77","doi-asserted-by":"publisher","first-page":"116822","DOI":"10.1016\/j.celrep.2025.116822","volume":"45","author":"A Power","year":"2026","unstructured":"Power A, Stierli S, Harford-Wright E, M\u00f2dol-Caballero G, Lloyd E, Kouloulia S, et al. Microenvironmental TGF-\u03b2 is an early driver of NF1-associated tumor formation. Cell Rep. 2026;45(1):116822.","journal-title":"Cell Rep"},{"issue":"16","key":"298_CR78","doi-asserted-by":"publisher","first-page":"2421","DOI":"10.1093\/hmg\/ddl165","volume":"15","author":"FC Yang","year":"2006","unstructured":"Yang FC, Chen S, Clegg T, Li X, Morgan T, Estwick SA, et al. Nf1+\/- mast cells induce neurofibroma like phenotypes through secreted TGF-beta signaling. Hum Mol Genet. 2006;15(16):2421\u201337.","journal-title":"Hum Mol Genet"},{"issue":"38","key":"298_CR79","doi-asserted-by":"publisher","first-page":"61500","DOI":"10.18632\/oncotarget.11133","volume":"7","author":"CP Liao","year":"2016","unstructured":"Liao CP, Pradhan S, Chen Z, Patel AJ, Booker RC, Le LQ. The role of nerve microenvironment for neurofibroma development. Oncotarget. 2016;7(38):61500\u20138.","journal-title":"Oncotarget"},{"issue":"10","key":"298_CR80","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.3390\/cancers13102329","volume":"13","author":"A Errico","year":"2021","unstructured":"Errico A, Stocco A, Riccardi VM, Gambalunga A, Bassetto F, Grigatti M, et al. Neurofibromin Deficiency and Extracellular Matrix Cooperate to Increase Transforming Potential through FAK-Dependent Signaling. Cancers (Basel). 2021;13(10):2329.","journal-title":"Cancers (Basel)"},{"issue":"32","key":"298_CR81","doi-asserted-by":"publisher","first-page":"4609","DOI":"10.1038\/sj.onc.1210261","volume":"26","author":"LQ Le","year":"2007","unstructured":"Le LQ, Parada LF. Tumor microenvironment and neurofibromatosis type I: connecting the GAPs. Oncogene. 2007;26(32):4609\u201316.","journal-title":"Oncogene"},{"issue":"2","key":"298_CR82","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1182\/blood-2009-09-242875","volume":"116","author":"K Staser","year":"2010","unstructured":"Staser K, Yang FC, Clapp DW. Mast cells and the neurofibroma microenvironment. Blood. 2010;116(2):157\u201364.","journal-title":"Blood"},{"issue":"24","key":"298_CR83","first-page":"8573","volume":"63","author":"ML Bajenaru","year":"2003","unstructured":"Bajenaru ML, Hernandez MR, Perry A, Zhu Y, Parada LF, Garbow JR, et al. Optic nerve glioma in mice requires astrocyte Nf1 gene inactivation and Nf1 brain heterozygosity. Cancer Res. 2003;63(24):8573\u20137.","journal-title":"Cancer Res"},{"issue":"10","key":"298_CR84","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/j.neo.2015.10.002","volume":"17","author":"AC Solga","year":"2015","unstructured":"Solga AC, Pong WW, Kim KY, Cimino PJ, Toonen JA, Walker J, et al. RNA Sequencing of Tumor-Associated Microglia Reveals Ccl5 as a Stromal Chemokine Critical for Neurofibromatosis-1 Glioma Growth. Neoplasia. 2015;17(10):776\u201388.","journal-title":"Neoplasia"},{"issue":"9","key":"298_CR85","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1093\/hmg\/ddm059","volume":"16","author":"GC Daginakatte","year":"2007","unstructured":"Daginakatte GC, Gutmann DH. Neurofibromatosis-1 (Nf1) heterozygous brain microglia elaborate paracrine factors that promote Nf1-deficient astrocyte and glioma growth. Hum Mol Genet. 2007;16(9):1098\u2013112.","journal-title":"Hum Mol Genet"},{"issue":"1","key":"298_CR86","doi-asserted-by":"publisher","first-page":"E8","DOI":"10.3171\/2009.11.FOCUS09221","volume":"28","author":"ON Gottfried","year":"2010","unstructured":"Gottfried ON, Viskochil DH, Couldwell WT. Neurofibromatosis Type 1 and tumorigenesis: molecular mechanisms and therapeutic implications. Neurosurg Focus. 2010;28(1):E8.","journal-title":"Neurosurg Focus"},{"issue":"29","key":"298_CR87","doi-asserted-by":"publisher","first-page":"9948","DOI":"10.1074\/jbc.RA119.010981","volume":"295","author":"JA Mund","year":"2020","unstructured":"Mund JA, Park S, Smith AE, He Y, Jiang L, Hawley E, et al. Genetic disruption of the small GTPase RAC1 prevents plexiform neurofibroma formation in mice with neurofibromatosis type 1. J Biol Chem. 2020;295(29):9948\u201358.","journal-title":"J Biol Chem"},{"issue":"5","key":"298_CR88","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/j.ceb.2010.08.015","volume":"22","author":"M Egeblad","year":"2010","unstructured":"Egeblad M, Rasch MG, Weaver VM. Dynamic interplay between the collagen scaffold and tumor evolution. Curr Opin Cell Biol. 2010;22(5):697\u2013706.","journal-title":"Curr Opin Cell Biol"},{"issue":"1","key":"298_CR89","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s40478-020-01103-4","volume":"9","author":"JP Brosseau","year":"2021","unstructured":"Brosseau JP, Sathe AA, Wang Y, Nguyen T, Glass DA, Xing C, et al. Human cutaneous neurofibroma matrisome revealed by single-cell RNA sequencing. Acta Neuropathol Commun. 2021;9(1):11.","journal-title":"Acta Neuropathol Commun"},{"issue":"4","key":"298_CR90","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1111\/j.1440-1789.2011.01276.x","volume":"32","author":"C Hagel","year":"2012","unstructured":"Hagel C, Behrens T, Prehm P, Schnabel C, Glatzel M, Friedrich RE. Hyaluronan in intra-operative edema of NF1-associated neurofibromas. Neuropathology. 2012;32(4):406\u201314.","journal-title":"Neuropathology"},{"issue":"1","key":"298_CR91","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s11060-016-2150-9","volume":"129","author":"NX Bonne","year":"2016","unstructured":"Bonne NX, Vitte J, Chareyre F, Karapetyan G, Khankaldyyan V, Tanaka K, et al. An allograft mouse model for the study of hearing loss secondary to vestibular schwannoma growth. J Neurooncol. 2016;129(1):47\u201356.","journal-title":"J Neurooncol"},{"issue":"2","key":"298_CR92","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1007\/s00401-016-1583-8","volume":"132","author":"A Schulz","year":"2016","unstructured":"Schulz A, B\u00fcttner R, Hagel C, Baader SL, Kluwe L, Salamon J, et al. The importance of nerve microenvironment for schwannoma development. Acta Neuropathol. 2016;132(2):289\u2013307.","journal-title":"Acta Neuropathol"},{"issue":"1","key":"298_CR93","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1038\/s41467-023-37226-0","volume":"14","author":"C Chiasson-MacKenzie","year":"2023","unstructured":"Chiasson-MacKenzie C, Vitte J, Liu CH, Wright EA, Flynn EA, Stott SL, et al. Cellular mechanisms of heterogeneity in NF2-mutant schwannoma. Nat Commun. 2023;14(1):1559.","journal-title":"Nat Commun"},{"issue":"1","key":"298_CR94","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s00401-025-02883-6","volume":"149","author":"F Zhao","year":"2025","unstructured":"Zhao F, Teng XF, Zhang J, Li SW, Wang LM, Zhao HG, et al. Multiplatform molecular analyses reveal two molecular subgroups of NF2-related schwannomatosis vestibular schwannomas with distinct tumour microenvironment and therapeutic vulnerabilities. Acta Neuropathol. 2025;149(1):47.","journal-title":"Acta Neuropathol"},{"issue":"5","key":"298_CR95","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1007\/s11912-023-01388-3","volume":"25","author":"EC Cumpston","year":"2023","unstructured":"Cumpston EC, Rhodes SD, Yates CW. Advances in Targeted Therapy for Neurofibromatosis Type 2 (NF2)-Associated Vestibular Schwannomas. Curr Oncol Rep. 2023;25(5):531\u20137.","journal-title":"Curr Oncol Rep"},{"issue":"2","key":"298_CR96","doi-asserted-by":"publisher","first-page":"224","DOI":"10.3390\/cancers18020224","volume":"18","author":"BS Zhang","year":"2026","unstructured":"Zhang BS, Lu S, Plotkin SR, Xu L. Advancements in Preclinical Models for NF2-Related Schwannomatosis Research. Cancers (Basel). 2026;18(2):224.","journal-title":"Cancers (Basel)"}],"container-title":["Laboratory Animal Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s42826-026-00298-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s42826-026-00298-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s42826-026-00298-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T07:02:05Z","timestamp":1789887725000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s42826-026-00298-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,20]]},"references-count":96,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["298"],"URL":"https:\/\/doi.org\/10.1186\/s42826-026-00298-2","relation":{},"ISSN":["2233-7660"],"issn-type":[{"value":"2233-7660","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,20]]},"assertion":[{"value":"26 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"36"}}